In addition, TGF-β receptor maturation may be disrupted by mediator protein complex subunit 12 (MED12), which leads to activation of TGF-β signaling pathway and upregulation of mesenchymal marker expression, further conferring chemotherapeutic tolerance in CRC patients [217]. Here, MED12 is linked to colorectal carcinoma.